Agents were informed that they would no longer receive commissions for select signs up as of November 1.
The National Association of Benefits and Insurance Professionals (NABIP) issued a statement in response to Aetna and Elevance Health (Anthem) announcing that as of November 1, they would no longer pay commissions for new enrollment for select Medicare plans.1
In a press release, NABIP CEO Jessica Brooks-Woods said, “By eliminating agent commissions in certain Medicare plans, Aetna and Anthem have created a substantial barrier for seniors who rely on agents to understand their plan options, manage costs, and access the care they need. This disruption hits particularly hard at a time when seniors are already grappling with higher prescription costs and shrinking benefits in their Medicare Advantage plans.”
She continued, “Our Medicare agents are essential advocates who help beneficiaries make informed coverage decisions, assist with navigating plan changes, and resolve complex claim issues, providing stability and support that is now at risk. Without assistance from Medicare agents, beneficiaries could face significant challenges that could compromise their access to personalized guidance and cost-effective choices.”
According to the NABIP, some agents and brokers were only notified of the change with less than 24 hours notices.
Brooks-Woods continued, “We call on Aetna, Anthem, and other industry leaders to collaborate with NABIP to find a sustainable solution that maintains the critical support our seniors need. Together, we can protect access to knowledgeable Medicare guidance, ensuring our healthcare system remains accessible, reliable, and dignified for all. NABIP reiterates its commitment to supporting agents, brokers, and the communities they serve through our Healthcare Bill of Rights. Our mission is to ensure that every American has access to quality, affordable healthcare guided by professionals who prioritize patient advocacy and equitable healthcare solutions."
The NABIP first announced its Healthcare Bill of Rights in March of this year.2 The goal of the initiative was to provide guidelines that would improve healthcare delivery systems for all Americans.
In a press release issued at the time, Brooks-Woods said, “NABIP's Healthcare Bill of Rights articulates the core values and principles of the association. They represent not just our beliefs but NABIP's commitment to ensuring that every American is empowered with the right to high-quality, affordable healthcare. These rights stand as the pillars by which we define our mission, measure our progress, and drive toward a future where equitable healthcare is not a privilege but a standard for all."
She continued, “The announcement of NABIP's Healthcare Bill of Rights took place at our recent Capitol Conference, showcasing NABIP's dedication to shaping a healthcare system that prioritizes the well-being and rights of all Americans. This significant milestone is a cornerstone in our commitment to creating a healthcare landscape that is privately accessible and affordable for every citizen."
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.